An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.
Algorithms for grading acute graft-versus-host disease (GVHD) are inaccurate in assessing mortality risk. We developed a method to predict mortality by using data from 386 patients with acute GVHD. From the onset of GVHD to day 100, GVHD manifestations were scored for the skin, liver, and upper and lower gastrointestinal tract, and data were recorded for immunosuppressive treatment, performance, and fever. Logistic regression models predicting nonrelapse mortality (NRM) at day 200 were developed with data from 193 randomly selected patients and then validated in the remaining 193 patients. Clinical parameters were grouped to optimize predictive accuracy measured as the area under a receiver-operator characteristic (ROC) curve. The optimal model included the total serum bilirubin concentration, oral intake, need for treatment with prednisone, and performance score. When the overall burden of GVHD was measured by using average Acute GVHD Activity Index (aGVHDAI) scores for each patient in training and validation data sets, areas under ROC curves were 0.87 and 0.85, respectively. Contour lines were generated to reflect the predicted NRM at day 200 as a function of current aGVHDAI scores. These results demonstrate that clinical manifestations of GVHD severity can be used to accurately predict the risk of NRM in real time.
Leisenring
Wendy M
WM
Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, 98109, USA.
Martin
Paul J
PJ
Petersdorf
Effie W
EW
Regan
Anne E
AE
Aboulhosn
Nada
N
Stern
Jean M
JM
Aker
Saundra N
SN
Salazar
Raymond C
RC
McDonald
George B
GB
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000465:Algorithms; D001663:Bilirubin / Q000097:blood; D002648:Child; D002675:Child, Preschool; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000401:mortality* / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality*; D006801:Humans; D007223:Infant; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012372:ROC Curve; D012720:Severity of Illness Index; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods
D019653:Myeloablative Agonists; D001663:Bilirubin; D011241:Prednisone